India's first allogeneic cell and gene therapy (CAR-NK & CAR-gamma delta T cell) company
East Ocyon Bio is India’s first allogeneic cell and gene therapy startup, developing CAR-NK and CAR-gamma delta T cell therapies for difficult-to-treat solid tumors and autoimmune diseases. Having completed in vitro studies and initiated in vivo efficacy studies with Tata ACTREC and NARFBR-ICMR, the company is now establishing a clinical-grade GMP facility for GLP tox and Phase I trials.
East Ocyon promoters have put 6.37 Cr of own funding and have raised seed fund of 35 Cr INR till date. The marquee investors include Micro Labs (one of the top pharma companies in India) and Aeravti Ventures (niche VC based in Bangalore, India).
We have filed three patents, and two more are currently under the filing process, totaling five patents by December 2025. The areas covered include novel antibody scFv sequences for CD19 and CD70, as well as a construct and process patent for our first product, Anti-PDL1 CAR-NK.
We are one of the few DSIR recognised R&D startups in India. We also have startup registration, Haryana MSME. We've been selected for the Saudi Venture Readiness Program 2025.
A team of 22 full-time scientists (60% women scientists, 50% Ph.D.s and Post-Doc qualified) and 7 advisors from India, the U.S., and the E.U. is supported by founders with strong backgrounds from AIIMS New Delhi, AFMC Pune, ISB Hyderabad, and extensive biotech experience.
Director & Co-founder
CEO & Co-founder
Director
